Realseq Biosciences, Inc.
Santa Cruz, CA
- UEI
- F8F5KUUPFG29
- CAGE
- 8AZ78
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2125 Delaware Ave B, Santa Cruz, CA 95060, USA
- Website
- realseqbiosciences.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Claret Bioscience LLC | Worcester, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Sansimeon, Inc. | Wilmington, DE | — |
| Electronic Biosciences, Inc. | San Diego, CA | 541330 Engineering Services |
| Partillion Bioscience Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mission Bio, Inc. | South San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Realseq Biosciences, Inc. (Realseq Biosciences Division), based in Santa Cruz, California, is a for-profit research organization that develops sequencing library preparation kits and analytical methods for cell-free RNA detection and characterization as a federal grant recipient under the National Institutes of Health. The vendor operates exclusively as a prime recipient on federal research grants; it holds no federal contracts, contract vehicles, or subcontract positions.
Realseq's federal grant portfolio concentrates entirely within the National Institutes of Health, specifically the National Human Genome Research Institute (NHGRI) and the National Institute of General Medical Sciences (NIGMS). The vendor has received four awards from NHGRI and one from NIGMS across five total prime grants since 2015, accounting for 100% of its federal awards. Combined obligated dollars across all awards total $6 million.
The vendor's recent and current work centers on developing proprietary sequencing library preparation platforms for comprehensive RNA fragmentome analysis in cancer biomarker detection. Representative active grants include a project titled "Advanced Approach for Target Small RNAs Enrichment from Biological Samples and Sequencing Library Preparation (TSR-SEQ) — Cell-Free RNAs" awarded by NHGRI with an award date of September 1, 2026 and ultimate completion date of August 31, 2027; a multi-year NHGRI project on "Preparation of Sequencing Libraries for Multi-Analyte Analysis of RNAs" awarded September 21, 2023 with completion scheduled for July 31, 2027, which focuses on developing the REALSEQ-RF platform to profile cell-free RNA fragmentomes and individual RNA fragment types; and an NHGRI project on "Preparation of Sequencing Libraries for Multi-Analyte Analysis of Small RNAs" awarded September 21, 2023 with completion scheduled for June 20, 2024, addressing technical gaps in detecting and discriminating small RNA classes with varying phosphorylation states. Two grants reach ultimate completion within the next twenty-four months and face potential recompete in that window.
Quick answers
Is Realseq Biosciences, Inc. registered in SAM.gov?
Yes. Realseq Biosciences, Inc.'s SAM.gov registration is active through January 26, 2027.
What is Realseq Biosciences, Inc.'s most recent federal award?
Realseq Biosciences, Inc.'s most recent federal grant award is Advanced approach for target small rnas enrichment from biological samples and sequencing library preparation (TSR-SEQ)… (R43CA314894), from National Cancer Institute (NIH), on September 1, 2026.
On GovTribe
See Realseq Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors